Recorded enzyme and transporter findings by polarity

Medicine–counterparty–role groups

8,404

Source sentence records

20,358

Asserted sentences

4,700

Denied sentences

7,494

Polarity not recorded

8,164

Medicines represented

755

Counterparties represented

36

Corpus records considered

9,855

All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.

inducer groups

617

inhibitor groups

3,131

not_recorded groups

3,074

substrate groups

1,582

• A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
• This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
• ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
• A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
• 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
• Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
• 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
• 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
• The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
• The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
• A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
• Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Showing 991–1,000 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

1. Projected row 991

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   BSEP

   Role

   NOT_RECORDED

   Asserted sentences

   0

   Denied sentences

   0

   Polarity not recorded

   2

   Complete sentence records

   1. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .

   2. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .

2. Projected row 992

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   CYP1A2

   Role

   INDUCER

   Asserted sentences

   0

   Denied sentences

   2

   Polarity not recorded

   0

   Complete sentence records

   1. NEGATED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Drug-Metabolizing Enzyme Induction Brivaracetam at concentrations up to 10 μM caused little or no change of mRNA expression of CYP1A2, 2B6, 2C9, 2C19, 3A4, and epoxide hydrolase.

   2. NEGATED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Drug-Metabolizing Enzyme Induction Brivaracetam at concentrations up to 10 μM caused little or no change of mRNA expression of CYP1A2, 2B6, 2C9, 2C19, 3A4, and epoxide hydrolase.

3. Projected row 993

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   CYP1A2

   Role

   NOT_RECORDED

   Asserted sentences

   0

   Denied sentences

   0

   Polarity not recorded

   2

   Complete sentence records

   1. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In Vitro Assessment of Drug Interactions Drug-Metabolizing Enzyme Inhibition Brivaracetam did not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, or 3A4.

   2. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In Vitro Assessment of Drug Interactions Drug-Metabolizing Enzyme Inhibition Brivaracetam did not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, or 3A4.

4. Projected row 994

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   CYP2C19

   Role

   INDUCER

   Asserted sentences

   2

   Denied sentences

   0

   Polarity not recorded

   0

   Complete sentence records

   1. ASSERTED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Co-administration with rifampin decreases brivaracetam plasma concentrations by 45%, an effect that is probably the result of CYP2C19 induction [see Dosage and Administration (2.6) and Drug Interactions (7.1) ] .

   2. ASSERTED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Co-administration with rifampin decreases brivaracetam plasma concentrations by 45%, an effect that is probably the result of CYP2C19 induction [see Dosage and Administration (2.6) and Drug Interactions (7.1) ] .

5. Projected row 995

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   CYP2C19

   Role

   INHIBITOR

   Asserted sentences

   2

   Denied sentences

   0

   Polarity not recorded

   0

   Complete sentence records

   1. ASSERTED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      CYP2C19 poor metabolizers and patients using inhibitors of CYP2C19 may require dose reduction.

   2. ASSERTED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      CYP2C19 poor metabolizers and patients using inhibitors of CYP2C19 may require dose reduction.

6. Projected row 996

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   CYP2C19

   Role

   NOT_RECORDED

   Asserted sentences

   0

   Denied sentences

   0

   Polarity not recorded

   6

   Complete sentence records

   1. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      The hydroxylation pathway is mediated primarily by CYP2C19.

   2. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      In human subjects possessing genetic variations in CYP2C19, production of the hydroxy metabolite is decreased 2-fold or 10-fold, while the blood level of brivaracetam itself is increased by 22% or 42%, respectively, in individuals with one or both mutated alleles.

   3. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam weakly inhibited CYP2C19 and would not be expected to cause significant inhibition of CYP2C19 in humans.

   4. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      The hydroxylation pathway is mediated primarily by CYP2C19.

   5. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      In human subjects possessing genetic variations in CYP2C19, production of the hydroxy metabolite is decreased 2-fold or 10-fold, while the blood level of brivaracetam itself is increased by 22% or 42%, respectively, in individuals with one or both mutated alleles.

   6. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam weakly inhibited CYP2C19 and would not be expected to cause significant inhibition of CYP2C19 in humans.

7. Projected row 997

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   CYP2C9

   Role

   NOT_RECORDED

   Asserted sentences

   0

   Denied sentences

   0

   Polarity not recorded

   2

   Complete sentence records

   1. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      An additional hydroxy acid metabolite is created by hydrolysis of the amide moiety on the hydroxy metabolite or hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9).

   2. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      An additional hydroxy acid metabolite is created by hydrolysis of the amide moiety on the hydroxy metabolite or hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9).

8. Projected row 998

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   MATE1

   Role

   NOT_RECORDED

   Asserted sentences

   0

   Denied sentences

   0

   Polarity not recorded

   2

   Complete sentence records

   1. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .

   2. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .

9. Projected row 999

   Medicine slug

   brivaracetam

   Medicine name

   Brivaracetam

   Enzyme or transporter

   MATE2

   Role

   NOT_RECORDED

   Asserted sentences

   0

   Denied sentences

   0

   Polarity not recorded

   2

   Complete sentence records

   1. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .

   2. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
      FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

      Brivaracetam label

      Version not recorded · Effective date not recorded

      Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .

10. Projected row 1000

    Medicine slug

    brivaracetam

    Medicine name

    Brivaracetam

    Enzyme or transporter

    OAT1

    Role

    NOT_RECORDED

    Asserted sentences

    0

    Denied sentences

    0

    Polarity not recorded

    2

    Complete sentence records

    1. NOT_RECORDED·pharmacokinetics·Retrieved 2026-08-30
       FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

       Brivaracetam label

       Version not recorded · Effective date not recorded

       Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .

    2. NOT_RECORDED·clinical_pharmacology·Retrieved 2026-08-30
       FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)

       Brivaracetam label

       Version not recorded · Effective date not recorded

       Brivaracetam did not inhibit or weakly inhibit BCRP, BSEP, MATE1, MATE2/K, MRP2, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or P-gp, suggesting that brivaracetam is unlikely to inhibit these transporters in vivo .